TVARDI THERAPEUTICS INC
TVRDNASDAQ🏆 #3603 by market capUS Equity
$1.76▼ $0.00 (−0.28%)
Market closed · at close1h—
24h▼ 0.3%
7d▼ 12.0%
14d▼ 17.8%
30d▼ 47.2%
1y▼ 92.7%
🏦Market Cap
$22M
Small Cap
📈Revenue Growth (YoY)
-79.0%
Declining
📊Gross Margin
100.0%
High
💵FCF Margin
826.3%
Strong
⚖️P/S Ratio
5.3x
Fair
Otter Score
47
Weak
Trading Snapshot
- Day Range
- $1.74 – $1.77
- 52-Week Range
- $1.50 – $43.65
- Volume
- $2.44B
- Avg Volume
- $2.29B
- Shares Outstanding
- 12.5M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $982,333
- P/E Ratio
- —
- P/S Ratio
- 5.3x
- EPS (TTM)
- $-1.60
- Dividend Yield
- —
Why Investors Own TVRD
- ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$4M▲ +63.7% YoY
Gross Margin (TTM)
57.8%▼ −0.5% YoY
Operating Income (TTM)
$615,354▲ +63.7% YoY
Free Cash Flow (TTM)
$443,627▲ +63.7% YoY
About TVARDI THERAPEUTICS INC
A company profile for TVARDI THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
47/100
Analyst Price Target
ⓘAverage Target
$1.72
▼ −2.4% Downside
High Target$1.88
Low Target$1.59
Based on 26 analysts
Latest News & Updates
🚀
CNBC·2h ago
TVARDI THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift TVRD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
TVARDI THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.